Next Article in Journal
Regulatory Roles for Long ncRNA and mRNA
Next Article in Special Issue
Epigenetics and Colorectal Cancer Pathogenesis
Previous Article in Journal
A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
Previous Article in Special Issue
Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells
Cancers 2013, 5(2), 430-461; doi:10.3390/cancers5020430
Review

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma

1,* , 1, 1, 2, 1,† and 1,†,*
Received: 28 February 2013; in revised form: 3 April 2013 / Accepted: 8 April 2013 / Published: 15 April 2013
(This article belongs to the Special Issue Cancer Epigenetics)
View Full-Text   |   Download PDF [954 KB, uploaded 15 April 2013]   |   Browse Figures
Abstract: Multiple myeloma (MM) is an incurable B-cell malignancy. Therefore, new targets and drugs are urgently needed to improve patient outcome. Epigenetic aberrations play a crucial role in development and progression in cancer, including MM. To target these aberrations, epigenetic modulating agents, such as DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi), are under intense investigation in solid and hematological cancers. A clinical benefit of the use of these agents as single agents and in combination regimens has been suggested based on numerous studies in pre-clinical tumor models, including MM models. The mechanisms of action are not yet fully understood but appear to involve a combination of true epigenetic changes and cytotoxic actions. In addition, the interactions with the BM niche are also affected by epigenetic modulating agents that will further determine the in vivo efficacy and thus patient outcome. A better understanding of the molecular events underlying the anti-tumor activity of the epigenetic drugs will lead to more rational drug combinations. This review focuses on the involvement of epigenetic changes in MM pathogenesis and how the use of DNMTi and HDACi affect the myeloma tumor itself and its interactions with the microenvironment.
Keywords: multiple myeloma; epigenetics; histone deacetylase inhibitor; DNA-methyltransferase inhibitor multiple myeloma; epigenetics; histone deacetylase inhibitor; DNA-methyltransferase inhibitor
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Maes, K.; Menu, E.; Van Valckenborgh, E.; Van Riet, I.; Vanderkerken, K.; De Bruyne, E. Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma. Cancers 2013, 5, 430-461.

AMA Style

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E. Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma. Cancers. 2013; 5(2):430-461.

Chicago/Turabian Style

Maes, Ken; Menu, Eline; Van Valckenborgh, Els; Van Riet, Ivan; Vanderkerken, Karin; De Bruyne, Elke. 2013. "Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma." Cancers 5, no. 2: 430-461.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert